Current News

Contact | Print version | PDF version | Send article | RSS feed

Solvay and Berna Biotech sign a license agreement for vaccine against Pseudomonas aeruginosa in Cystic Fibrosis patients

04 Aug 2005 - Solvay Pharmaceuticals and Berna Biotech Ltd announced that they have signed a commercialization and license agreement for Aerugen®, a vaccine for the prevention of Pseudomonas aeruginosa (PA) infection in Cystic Fibrosis (CF) patients. The agreement complements Solvay Pharmaceuticals' CF product portfolio. Aerugen® has a particularly high value in the treatment of CF patients, for whom PA infection is a major cause of death.
 
Solvay Pharmaceuticals acquires the exclusive distribution rights for the USA, Canada, Latin America and some other countries.
 
The vaccine Aerugen® will be developed by Berna Biotech. The product has obtained Orphan Drug designation in USA. Berna will submit the FDA file and the launch in the USA is expected to take place by 2009. More countries will follow subsequently.